Literature DB >> 20528548

Growth hormone replacement therapy in adults with growth hormone deficiency: benefits and cost-effectiveness.

Fatih Tanriverdi1, Kursad Unluhizarci, Fahrettin Kelestimur.   

Abstract

In recent years, growth hormone deficiency in adults has been accepted as a clinical entity. Although beneficial effects of growth hormone replacement therapy (GHRT) in adults - including improvements in body composition, lipid profile, quality of life and bone mineral density - have been shown in many studies, there are still controversies and ongoing debates regarding GHRT in adults. It seems that this subject will continue to be a hot topic in the near future. Therefore, the aim of this review is to re-evaluate the current understanding on GHRT in adults in the light of recent data. Additionally, the clinical aspects, risks, benefits and cost-effectiveness of GHRT are summarized.

Entities:  

Year:  2006        PMID: 20528548     DOI: 10.1586/14737167.6.2.131

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN: 1473-7167            Impact factor:   2.217


  3 in total

1.  Prospective investigation of pituitary functions in patients with acute infectious meningitis: is acute meningitis induced pituitary dysfunction associated with autoimmunity?

Authors:  F Tanriverdi; A De Bellis; H Teksahin; E Alp; A Bizzarro; A A Sinisi; G Bellastella; V A Paglionico; A Bellastella; K Unluhizarci; M Doganay; F Kelestimur
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

2.  Hypopituitarism due to sports related head trauma and the effects of growth hormone replacement in retired amateur boxers.

Authors:  F Tanriverdi; K Unluhizarci; Z Karaca; F F Casanueva; F Kelestimur
Journal:  Pituitary       Date:  2010-06       Impact factor: 4.107

3.  Evaluation of long-term pituitary functions in patients with severe ventricular arrhythmia: a pilot study.

Authors:  Y Simsek; M G Kaya; F Tanriverdi; B Çalapkorur; H Diri; Z Karaca; K Unluhizarci; F Kelestimur
Journal:  J Endocrinol Invest       Date:  2014-08-09       Impact factor: 4.256

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.